ACERライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (21 11月 2023 @ 05:59):

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases...

Stats
本日の出来高	574 675
平均出来高	2.39M
時価総額	16.15M
EPS	$-0.600 ( 2024-03-25 )
次の収益日	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.342
ATR14	$0.0570 (8.64%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-17	Aselage Steve	Sell	483 741	Common Stock, $0.0001 par value per share
2023-11-17	Dunn John Michael	Sell	27 380	Common Stock, $0.0001 par value per share
2023-11-17	Joseph Donald	Sell	14 285	Common Stock, $0.0001 par value per share
2023-11-17	Schelling Chris	Sell	2 712 529	Common Stock, $0.0001 par value per share
2023-11-17	Palmin Harry S	Sell	125 000	Common Stock, $0.0001 par value per share

INSIDER POWER
-67.84
Last 96 transactions
Buy: 5 870 002 \| Sell: 3 622 222

ボリューム相関

長: 0.50 (weak)

短: -0.98 (very strong negative)

Signal:(30.163) Neutral

Acer Therapeutics Inc 相関

10 最も正の相関
BIRD	0.965
CNTY	0.965
COLB	0.964
FTXO	0.963
KBWB	0.962
AIRG	0.961
FITB	0.961
CPTN	0.96
PRCH	0.958
EVLO	0.957

10 最も負の相関
OPNT	-0.949
DVCR	-0.944
DSEY	-0.941
AMYT	-0.935
CCRC	-0.933
SUMO	-0.93
DAKT	-0.919
SGEN	-0.918
BTBD	-0.917
PPYAU	-0.913

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Acer Therapeutics Inc 相関 - 通貨/商品

0.07
( neutral )

-0.05
( neutral )

0.00
( neutral )

-0.01
( neutral )

0.36
( neutral )

-0.19
( neutral )

Acer Therapeutics Inc 財務諸表

Annual	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-1.770

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-1.770

FY	2021
収益:	$1.26M
総利益:	$0.00 (0.00 %)
EPS:	$-1.080

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-2.06

Financial Reports:

No articles found.

Acer Therapeutics Inc

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.